Similarly, Cavelti-Weder et al. [170] evaluated the safety and biological activity of the human monoclonal anti-IL-1β antibody gevokizumab in a placebo-controlled, dose-escalation study involving a total of 98 patients with T2D. This evidence concerns the gene IL1B and type 2 diabetes mellitus.